Key result
Treatment with dapagliflozin significantly decreased P2Y12 reaction units by a mean difference of 36.70 compared to baseline in patients with stable CAD and T2DM on DAPT.
Why the study?
The study was conducted to assess the pharmacodynamic effect of the SGLT2 inhibitor dapagliflozin on platelet reactivity in diabetic patients.
Does dapagliflozin 10 mg once-daily reduce platelet reactivity in diabetic patients?
Population
Diabetic patients
Comparison
Dapagliflozin 10 mg once daily vs prior to initiation
Design
Prospective pharmacodynamic pilot study
Follow-up
10 days
Authors
Loading...
May indicate adjunctive antiplatelet effects in T2DM with CAD on DAPT; leaves open confirmation in randomized outcome trials.
Does dapagliflozin 10 mg once-daily reduce platelet reactivity in diabetic patients?
Mean Difference: 36.7 (95% CI 16.66–56.75)
Absolute Event Rate: 160.93% vs 197.63%
p-value: p=0.001
Dapagliflozin 10 mg daily for 10 days significantly reduced platelet reactivity in diabetic patients, suggesting a potential adjunctive antiplatelet effect.
Seecheran et al. (2021) studied Stable coronary artery disease and type 2 diabetes mellitus (n=27). Dapagliflozin vs. Baseline (without dapagliflozin) was evaluated on P2Y12 reaction units (PRU) (MD 36.70, 95% CI 16.66-56.75, p=0.001). Treatment with dapagliflozin significantly decreased P2Y12 reaction units by a mean difference of 36.70 compared to baseline in patients with stable CAD and T2DM on DAPT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: